IMUX Stock — Immunic Inc

Immunic Inc (IMUX)

Updated October 16, 2026.

IMUX is a Stock. Total return is -99.9% over the past 12.5 years, 504.4 points behind SPY at 404.5%.

Immunic is a biotechnology company developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases, with its lead candidate IMU-838 in Phase 3 clinical trials for multiple sclerosis and ulcerative colitis, along with earlier-stage programs for gastrointestinal conditions. The company does not currently distribute dividends. Immunic appeals to investors seeking exposure to clinical-stage biotech development rather than those dependent on current income.

IMUX performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 12.5 years, 504.4 points behind SPY at 404.5%. Over the past year its total return — price change plus distributions reinvested — is -14.6%. Its deepest 1-year drawdown was 60.6%.

IMUX key facts

Asset type

Stock

Asset class

Equity

Inception date

04/17/2014

Distribution frequency

None

Last close

$6.97 (as of 2026-10-16)

Market cap

$95,101,935

Average volume

366215.0

Payment date

04/15/2019

Beta

1.412

Payout ratio

0.0%

EPS

$-3.55

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IMUX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 60.6%.

Who may consider IMUX — and who may not

It is a weaker fit for investors who need monthly cash flow (IMUX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IMUX

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions